Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01649947 | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | completed | Phase 2 | 32 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers Squibb |
| 13 |
| Nov 14, 2022 |
| clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | completed | Phase 1 / Phase 2 | 267 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03900117 | Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC | completed | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT02448225 | 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules | completed | Phase 2 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02898116 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | completed | Phase 1 / Phase 2 | 61 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT00054314 | BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | — | Roswell Park Cancer InstituteOTHER | 0 | Sep 26, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | completed | Phase 1 / Phase 2 | 141 | Syndax PharmaceuticalsINDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT00970684 | Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 13 | Nathan Pennell, MD, PhDOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT02716311 | Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer(ACE-Lung) | completed | Phase 2 | 118 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02328105 | LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT00553800 | Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03623750 | E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C(EPICAL) | completed | Phase 1 / Phase 2 | 23 | Instituto Oncológico Dr RosellOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04507906 | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | completed | Phase 1 / Phase 2 | 21 | Shanghai Chest HospitalOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT00097851 | Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 100 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00103389 | Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 98 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT02920476 | TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | completed | Phase 2 | 4 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT00376623 | Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 96 | Boehringer IngelheimINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02183870 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer(EUCROSS) | completed | Phase 2 | 34 | University of CologneOTHER | 3 | Jun 16, 2022 | clinicaltrials |
| NCT00979212 | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | completed | Phase 2 | 71 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 40 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT00750269 | Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 120 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | completed | Phase 2 | 43 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Jun 6, 2022 | clinicaltrials |
| NCT02684461 | Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | completed | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03812809 | A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive | completed | Phase 2 | 226 | Beta Pharma ShanghaiINDUSTRY | 1 | May 19, 2022 | clinicaltrials |
| NCT00887783 | Navelbine And Radiotherapy in Locally Advanced Lung Cancer(NARLAL) | completed | Phase 2 | 117 | Odense University HospitalOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT03386955 | BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 215 | Beta Pharma ShanghaiINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT00364780 | Study of XL647 in Subjects With Non-Small-Cell Lung Cancer | completed | Phase 2 | 55 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT00522145 | Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib | completed | Phase 2 | 41 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | completed | Phase 1 / Phase 2 | 105 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT00456261 | First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC | completed | Phase 2 | 110 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03268057 | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer(CLASSICAL-Lung) | completed | Phase 1 / Phase 2 | 62 | Vaccinex Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT03562871 | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | completed | Phase 1 / Phase 2 | 109 | IO BiotechINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00152477 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | completed | Phase 2 | 165 | UCB PharmaINDUSTRY | 3 | Apr 12, 2022 | clinicaltrials |
| NCT01003964 | Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV | completed | Phase 2 | 289 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01156545 | BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC | completed | Phase 2 | 68 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02417701 | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02616393 | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases | completed | Phase 2 | 36 | Kadmon Corporation, LLCINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2022source: clinicaltrials